Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price was up 4.4% on Friday . The stock traded as high as $4.57 and last traded at $4.53, with a volume of 304,077 shares trading hands. The stock had previously closed at $4.34.

Several equities analysts have recently weighed in on GNCA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a research note on Friday, April 1st. FBR & Co reissued a “buy” rating and set a $17.00 price target on shares of Genocea Biosciences in a research report on Friday, April 1st. Stifel Nicolaus boosted their price target on Genocea Biosciences from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, April 1st. Finally, Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $18.13.

The firm’s market cap is $125.28 million. The stock’s 50-day moving average price is $4.20 and its 200 day moving average price is $4.36.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.07. On average, equities research analysts anticipate that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current year.

An institutional investor recently raised its position in Genocea Biosciences stock. AWM Investment Company Inc. raised its stake in shares of Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned about 2.54% of Genocea Biosciences worth $3,768,000 as of its most recent SEC filing.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.